Takeda Pharmaceuticals North America, Inc., a pharmaceutical company, offers products for oral diabetes, insomnia, and gastroenterology treatments in the United States. The company offers ACTOS, an insulin sensitizer for people with type 2 diabetes. ACTOS is also used as monotherapy to lower blood glucose, and in combination with sulfonylurea, metformin, or insulin for glycemic control. The company also provides ACTOplus met, which combines ACTOS and metformin, which are used for type 2 diabetes medications; Duetact that combines ACTOS and glimepiride for using in diabetes medications with complementary actions; AMITIZA, a soft-gel capsules for the treatment of chronic idiopathic constipation in adults; and ROZEREM, which are the tablets for treatment of insomnia characterized by difficulty with sleep onset. In addition, it offers products for diabetes, insomnia, cardiovascular diseases, and gastrointestinal disorders, as well as for therapeutic area, human papillomavirus, CRSD/Alzheimer’s sleep/wake disturbance, diabetic neuropathy, hypertension, post-herpetic neuralgia, chronic kidney disease/cancer-related anemia, hyperlipidemia, diabetes mellitus, gastric cancer, non-small cell lung cancer, and colorectal cancer. The company was founded in 1998 and is headquartered in Deerfield, Illinois. Takeda Pharmaceuticals North America, Inc. operates as a subsidiary of Takeda Chemical Industries, Ltd.